Sunshine Biopharma (SBFM) AI Stock Analysis

• Market Cap: $5.79M
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.77
• Revenue Growth: 13.24%
• EPS Growth: 98.80%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.19
• Shares Outstanding: 4,905,945
• 10 Day Avg. Volume: 3,175,467
• 30 Day Avg. Volume: 1,091,586
• PEG Ratio: <0.01
• Price to Book (P/B): 0.09
• Price to Sales (P/S): 0.06
• P/FCF Ratio: -0.14
• Enterprise Value/Market Cap: -0.46
• Enterprise Value/Revenue: -0.07
• Enterprise Value/Gross Profit: -0.22
• Enterprise Value/Ebitda: 0.43
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $1.00 ▼(-18.70% Downside)

Sunshine Biopharma's overall stock score is primarily impacted by its financial performance and valuation. The company faces significant profitability and cash flow challenges, reflected in a low financial performance score. The technical analysis indicates a bearish trend, while the negative P/E ratio and lack of dividend yield result in a poor valuation score. These factors collectively contribute to a low overall stock score.

Positive Factors

Conservative Capital Structure

Very low leverage provides durable financial flexibility for a biotech with long, capital-intensive development cycles. Low debt reduces fixed interest obligations, lowering bankruptcy risk and extending runway, which supports R&D continuity and partnership negotiations over months.

Stable Gross Margin

A consistent ~33% gross margin indicates structural pricing power or controllable COGS on the company’s products and formulations. This margin buffer helps absorb SG&A and R&D spend, supporting sustainable investment in pipelines and improving odds of progressing candidates without immediate margin erosion.

Partnership- and Licensing-Focused Model

A business model centered on partnerships and licensing reduces sole commercial execution risk and can provide non-dilutive funding, regulatory expertise, and market access. Strategically aligned collaborators can accelerate commercialization and de-risk late-stage investment needs over the medium term.

Negative Factors

Weak Cash Flow Generation

Sustained negative operating and free cash flows constrain the company’s ability to fund trials and operations internally, increasing reliance on external financing or partnerships. Over several months this raises dilution risk, limits strategic optionality, and can slow development timelines if cash remains tight.

Persistent Unprofitability

Ongoing negative net profit and EBIT margins show the business is not yet operationally self-sustaining. For a drug developer this means continued need for capital to reach commercialization, pressure on management to improve operating efficiency, and potential reprioritization of programs if losses persist.

Negative Return on Equity

Negative ROE signals the company is not generating returns on shareholder capital, undermining long-term investor value creation. Over a multi-month horizon this may force management to alter strategy, seek dilutive financing, or pursue asset sales/partnering to rectify capital inefficiency and restore investor confidence.

Sunshine Biopharma Business Overview & Revenue Model

Company Description

Sunshine Biopharma (SBFM) is a biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company operates within the biotechnology sector, where it specializes in drug discovery and development, particularly in the areas of oncology and related treatments. Sunshine Biopharma's core products include a pipeline of drug candidates that address unmet medical needs, leveraging advanced technologies to enhance therapeutic efficacy and patient outcomes.

How the Company Makes Money

Sunshine Biopharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company aims to secure funding through partnerships and collaborations with larger pharmaceutical firms, which can provide financial resources and market access for its drug candidates. Additionally, SBFM may generate income through licensing agreements that allow other companies to use its proprietary technologies or drug formulations. The company may also benefit from government grants and research funding aimed at supporting innovative biopharmaceutical research. As the company progresses in clinical trials and moves toward regulatory approvals, potential sales of its products could significantly contribute to its revenue streams.

Sunshine Biopharma Financial Statement Overview

Summary

Sunshine Biopharma is experiencing moderate revenue growth but faces significant profitability and cash flow challenges. The company's low leverage is a positive aspect, yet the negative return on equity and persistent losses highlight the need for strategic improvements. Strengthening operational efficiency and cash flow management will be crucial for future financial stability and growth.

Income Statement

Sunshine Biopharma's income statement shows a modest revenue growth of 2.7% in the TTM period, indicating some positive momentum. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively stable at 33.3%, but the persistent losses suggest challenges in managing operational costs effectively.

Balance Sheet

The balance sheet reflects a low debt-to-equity ratio of 0.035, indicating conservative leverage. However, the return on equity is negative, highlighting ongoing profitability issues. The equity ratio stands at a healthy level, suggesting a solid capital structure, but the company needs to improve its return metrics to enhance shareholder value.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a concerning free cash flow growth rate of -12.1% in the TTM period. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite a positive free cash flow to net income ratio, the overall cash flow position remains weak, necessitating better cash management strategies.

Breakdown	TTM	Dec 2024	Mar 2024	Mar 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.32M	34.87M	24.09M	4.35M	228.43K	71.41K
Gross Profit	12.32M	10.67M	8.34M	1.70M	110.60K	45.56K
EBITDA	-6.20M	-5.15M	-3.82M	-26.45M	-12.10M	-2.60M
Net Income	-5.99M	-5.13M	-4.51M	-26.74M	-12.44M	-2.78M
Balance Sheet
Total Assets	31.49M	30.56M	27.35M	29.55M	2.20M	1.05M
Cash, Cash Equivalents and Short-Term Investments	9.31M	9.69M	16.29M	21.83M	2.05M	997.48K
Total Debt	854.76K	952.48K	657.71K	765.26K	1.90M	1.91M
Total Liabilities	7.29M	7.06M	6.14M	7.92M	1.99M	2.00M
Stockholders Equity	24.20M	23.50M	21.21M	21.63M	211.66K	-954.84K
Cash Flow
Free Cash Flow	-8.33M	-14.85M	-9.56M	-5.55M	-1.83M	-658.49K
Operating Cash Flow	-7.12M	-12.53M	-8.78M	-5.25M	-1.83M	-657.30K
Investing Cash Flow	-1.32M	-2.32M	-656.15K	-14.62M	0.00	-1.19K
Financing Cash Flow	6.08M	9.29M	3.43M	39.47M	2.90M	1.61M

Sunshine Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Negative. The current price of 1.23 is above the 20-day moving average (MA) of 1.21, below the 50-day MA of 1.27, and below the 200-day MA of 1.47, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 42.04 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBFM.

Sunshine Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
YCBD	48 Neutral	$7.59M	-0.41	-44.42%	―	-1.50%	80.17%
SBFM	44 Neutral	$5.79M	-0.63	-24.34%	―	13.24%	98.80%
SNOA	44 Neutral	$4.86M	-1.39	-76.14%	―	25.02%	55.11%
IMCC	40 Underperform	$5.30M	-1.21	-93.87%	―	-0.74%	81.49%
SHPH	32 Underperform	$3.51M	-0.05	-9999.00%	―	―	79.31%

Sunshine Biopharma Corporate Events

Sunshine Biopharma Holds Annual Stockholders Meeting

On December 11, 2025, Sunshine Biopharma Inc. held its annual meeting of stockholders where key decisions were made. The company elected five directors, ratified the appointment of M&K CPAS, PLLC as its independent registered public accounting firm for 2025, and approved an amendment to increase the number of shares in its 2023 Equity Incentive Plan to 683,000. These actions are likely to impact the company’s governance and financial strategies moving forward.

The most recent analyst rating on (SBFM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Sunshine Biopharma stock, see the SBFM Stock Forecast page.